-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] News on August 8, according to data from Oriental Fortune Choice, today there are 36 stocks whose intraday stock prices hit a record high, mainly in pharmaceutical biology, calculators, basic chemicals, machinery and equipment, electronics and other industri.
Among them, in the field of pharmaceutical biology, a total of 2 pharmaceutical stocks hit a record high during the session, involving Yaokang Biology and Rongchang Biolo.
Yaokang Biopharmaceuticals closed at -9%, with a closing price of 33 yuan and a price-earnings ratio of 9
The stock was officially listed on the Science and Technology Innovation Board on April 25 this year, with an issue price of 253 yuan per share, and the net amount of funds raised was 026 billion yu.
On the first day of listing, the stock opened at 200 yuan per share, and it broke at the openi.
The current total market capitalization is 153 billi.
On the news, Yaokang Biology recently replied to investors on the interactive platform that the company is currently focusing on the research and development, production, sales and related technical services of experimental animal mouse models, and for new businesses such as life science downstream and non-human primat.
direction, the company is continuously tracking and researching relevant market opportuniti.
Internationalization is one of the company's core strategi.
The company has established the world's largest resource bank of mouse strai.
The quantity and quality of mouse models lead the wor.
With the establishment of market channels, the establishment of brand awareness, and the expansion of customer pools, overseas operating income Steady growth is expect.
According to the data, Yaokang Bio is an enterprise specializing in the research and development, production, sales and related technical services of experimental animal mouse mode.
In 2021, Yaokang Bio achieved operating income of 394 million yuan, a year-on-year increase of 535%; net profit attributable to shareholders of the parent company achieved a year-on-year increase of 645%, reaching 125 million yu.
Rongchang Bio Rongchang Bio closed up 4%, with a closing price of 661 yuan and a price-earnings ratio of 186
The stock was listed on the Hong Kong Stock Exchange on November 9, 2020, raising a total of 590 million US dollars, and then in March 202 It landed on the Science and Technology Innovation Board on the 31st and broke at the opening, at 46 yuan per share, opening 17% low.
Subsequently, its share price rose to the issue price of 48 yuan per share, but then fe.
According to the inquiry, the issue price of Rongchang Bio’s Hong Kong shares is HK$51 Since its listing, Rongchang Bio’s share price has risen from the issue price to an all-time high of HK$148 within 3 mont.
Yuan shares" era, the current total market value of 3988 billi.
On the news, the company recently announced that on August 5, 2022, it further entered into the Bank of Qingdao Wealth Management Product Agreement .
13 and the Bank of Qingdao Wealth Management Product Agreement .
14 with the Yantai Sub-branch of the Bank of Qingdao, pursuant to which the company agreed to use idle A shares to issue and raise fun.
The funds purchased RMB 30 million and RMB 60 million of wealth management products from Bank of Qingdao Yantai Sub-branch respective.
According to the data, Rongchang Bio is an innovative biopharmaceutical company with a global vision, focusing on the discovery and development of therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodi.
and commercializati.
The company provides safe, effective and accessible clinical solutions for major diseases such as autoimmune diseases, tumor diseases, and ophthalmic diseases to meet a large number of unmet clinical nee.
It is worth mentioning that Rongchang Bio is frequently favored by capit.
As early as November 2020, when Rongchang Bio landed on the Hong Kong Stock Exchange, it attracted nearly 20 large investment institutions including BlackRock, Aobo Capital, and Hillhouse Capit.
, setting a record for global biotech IPO fundraising in 202
The 2021 annual report shows that the company's operating income in 2021 will be 426 billion yuan, a year-on-year increase of 46,7531%; the profit attributable to shareholders of the parent company is 276 million yuan, a year-on-year increase of 135
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, in the field of pharmaceutical biology, a total of 2 pharmaceutical stocks hit a record high during the session, involving Yaokang Biology and Rongchang Biolo.
Yaokang Biopharmaceuticals closed at -9%, with a closing price of 33 yuan and a price-earnings ratio of 9
The stock was officially listed on the Science and Technology Innovation Board on April 25 this year, with an issue price of 253 yuan per share, and the net amount of funds raised was 026 billion yu.
On the first day of listing, the stock opened at 200 yuan per share, and it broke at the openi.
The current total market capitalization is 153 billi.
On the news, Yaokang Biology recently replied to investors on the interactive platform that the company is currently focusing on the research and development, production, sales and related technical services of experimental animal mouse models, and for new businesses such as life science downstream and non-human primat.
direction, the company is continuously tracking and researching relevant market opportuniti.
Internationalization is one of the company's core strategi.
The company has established the world's largest resource bank of mouse strai.
The quantity and quality of mouse models lead the wor.
With the establishment of market channels, the establishment of brand awareness, and the expansion of customer pools, overseas operating income Steady growth is expect.
According to the data, Yaokang Bio is an enterprise specializing in the research and development, production, sales and related technical services of experimental animal mouse mode.
In 2021, Yaokang Bio achieved operating income of 394 million yuan, a year-on-year increase of 535%; net profit attributable to shareholders of the parent company achieved a year-on-year increase of 645%, reaching 125 million yu.
Rongchang Bio Rongchang Bio closed up 4%, with a closing price of 661 yuan and a price-earnings ratio of 186
The stock was listed on the Hong Kong Stock Exchange on November 9, 2020, raising a total of 590 million US dollars, and then in March 202 It landed on the Science and Technology Innovation Board on the 31st and broke at the opening, at 46 yuan per share, opening 17% low.
Subsequently, its share price rose to the issue price of 48 yuan per share, but then fe.
According to the inquiry, the issue price of Rongchang Bio’s Hong Kong shares is HK$51 Since its listing, Rongchang Bio’s share price has risen from the issue price to an all-time high of HK$148 within 3 mont.
Yuan shares" era, the current total market value of 3988 billi.
On the news, the company recently announced that on August 5, 2022, it further entered into the Bank of Qingdao Wealth Management Product Agreement .
13 and the Bank of Qingdao Wealth Management Product Agreement .
14 with the Yantai Sub-branch of the Bank of Qingdao, pursuant to which the company agreed to use idle A shares to issue and raise fun.
The funds purchased RMB 30 million and RMB 60 million of wealth management products from Bank of Qingdao Yantai Sub-branch respective.
According to the data, Rongchang Bio is an innovative biopharmaceutical company with a global vision, focusing on the discovery and development of therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodi.
and commercializati.
The company provides safe, effective and accessible clinical solutions for major diseases such as autoimmune diseases, tumor diseases, and ophthalmic diseases to meet a large number of unmet clinical nee.
It is worth mentioning that Rongchang Bio is frequently favored by capit.
As early as November 2020, when Rongchang Bio landed on the Hong Kong Stock Exchange, it attracted nearly 20 large investment institutions including BlackRock, Aobo Capital, and Hillhouse Capit.
, setting a record for global biotech IPO fundraising in 202
The 2021 annual report shows that the company's operating income in 2021 will be 426 billion yuan, a year-on-year increase of 46,7531%; the profit attributable to shareholders of the parent company is 276 million yuan, a year-on-year increase of 135
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
